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Psoriasis is a disease characterized by chronic cuta-
neous inflammation and increased proliferation of ker-
atinocytes. Cutaneous homeostasis is clearly perturbed
in psoriasis. Alterations observed in psoriatic skin
include activation of resident and infiltrating cells,
expression of inflammatory mediators, their receptors
and adhesion molecules, and activation of intracellular
signal transducing pathways.1,2 Several lines of investi-
gation favour a contribution of the dermal fibroblast to
the pathophysiology of psoriasis. Experiments using
athymic nude mice showed that skin biopsies from 
psoriatic lesions, following transplantation onto these
mice, retained the major histologic features of pso-
riasis.3 Later on, combined grafting studies showed that
the classical characteristics of psoriasis only persisted
when psoriatic epidermis was transplanted together
with psoriatic dermis.4 Moreover, the rates of prolifer-
ation of normal and psoriatic human keratinocytes dif-
fer in vivo, but not in monoculture.5 It thus appeared
that psoriatic keratinocytes need to be in contiguity with
dermal fibroblasts to maintain epidermal hyperplasia
in vivo. Several groups observed that the growth of
human keratinocyte in vitro is supported by the use of
fibroblasts or even connective tissue-derived small mol-
ecular weight material.5,6 Furthermore, Saiag and col-
leagues found that upper dermal fibroblasts from
psoriasis patients cultured in a collagen lattice induced
hyperproliferation in normal epidermal biopsies.7
Reproducibility of this finding depends on the anatom-
ical location of the fibroblast (upper versus deeper 
dermis), the type of fibroblast culture (fibroblasts incor-
porated in collagen lattice versus monoculture) and epi-
dermal cell culture (biopsy versus monolayer) used in
the fibroblast-keratinocyte co-culture model.5,8,9 All
together, studies suggest the involvement of fibroblast-
derived cytokines in the pathogenesis of psoriasis. For
instance, human dermal fibroblasts are able to produce
interleukin(IL-)1, IL-6 and IL-8,10–12 which are not only
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Interleukin(lL-)6 is overproduced in psoriatic lesions. We investigated the contribution of
dermal fibroblasts to the local IL-6 production. Fibroblasts (passageno. 2 to 6) derived from
lesional psoriatic (PP) and normal human (NN) skin were used to analyse the secretion of
IL-6, and the related cytokines IL-1, IL-8 and TNF-a , and the expression of their corre-
sponding mRNA by bioassay, ELISA and Northern hybridization, respectively. PP fibro-
blasts cultured under serum-free conditions produced increased amounts of bioactive IL-6
when compared to NN fibroblasts. Differences were partially restored in the presence of
growth factors or serum. The serum-induced IL-6 production reached a maximum within 24
h after seeding and remained unchanged in PP fibroblasts, whereas comparable amounts of
IL-6 were produced only 6 days later in NN fibroblasts. There was a clear expression of IL-6
mRNA in both types of fibroblasts under serum-free conditions. Unexpectedly, fetal calf
serum, inactivated fetal calf serum as well as human serum completely inhibited the expres-
sion of IL-6 mRNA in all the PP fibroblast cultures investigated. NN fibroblasts were clearly
less sensitive to this inhibiting effect of serum. Furthermore, medium supplemented with
serum-free component or calcium also repressed IL-6 mRNA expression in PP fibroblasts in
contrast to NN fibroblasts. Cycloheximide fully restored the repressing effect of serum indi-
cating that serum induced a labile repressor protein. PP and NN fibroblasts produced negli-
gible amounts of IL-1 and TNF-a , but the production of IL-8, however, was comparable to
that of IL-6. Our results show a differently regulated IL-6 synthesis in PP fibroblasts in 
vitro, suggesting an active contribution of dermal fibroblasts to the local IL-6 production in
psoriasis.
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actively involved in inflammation but are also mitogenic
for epidermal cells.13–15 Espinoza and colleagues have
indeed shown that psoriatic fibroblasts produce elev-
ated amounts of IL-1b .16
We previously reported an elevated IL-6 bioactiv-
ity in psoriatic suction blister fluids but not in the cor-
responding serum samples.17 Analysis of IL-6 mRNA
of keratinocyte and fibroblast cultures indicated that
fibroblasts were the most likely cellular source for this
local IL-6 production. Reports on the altered epider-
mal IL-6 expression in psoriasis are conflicting.
Increased epidermal expression of IL-6 protein was
detected with immunochemistry and of IL-6 mRNA
with in situ hybridization using cultures of keratinocytes
as well as skin biopsies from active psoriatic plaques.14–l8
However, neither IL-6 protein nor IL-6 bioactivity
could be detected in scales from psoriatic lesions and,
using in situ hybridization, the increase of IL-6 mRNA
in lesional psoriatic epidermis could not be reproduced
by others.19,20 Furthermore, the presence of IL-6 mRNA
in epidermal keratome biopsies was only observed with
the sensitive PCR technique.22 Contaminating dermal
fibroblasts were assumed to be the source of the
increased IL-6 expression in lesional psoriatic ker-
atome biopsies.21
In the present study we therefore investigated the
secretion of IL-6 protein and expression of its RNA
using early passages of fibroblasts derived from lesional
psoriatic (PP) and normal control (NN) skin. The 
protein and mRNA expression of IL-1, IL-8 and 
tumor necrosis factor (TNF-)a were also studied.
Experiments were performed with media supple-
mented with calcium, growth factors, cytokines and 
several types of serum.
RESULTS
PP fibroblasts secrete low but increased amounts of
IL-6 compared to NN fibroblasts under serum-free
culture conditions
With a low-calcium (0.15 mM), serum-free medium
(medium 1: KBM/unsupplemented MCDB 153) PP and
NN fibroblasts hardly survived (Fig. 1B). However, low
but clearly detectable IL-6 levels were present in the
corresponding fibroblast-conditioned media. PP
fibroblasts secreted more bioactive IL-6 on each test
day (5 consecutive days starting from day 3 after seed-
ing), and on average about three times more IL-6 than
NN fibroblasts, as illustrated in Figure 1B. Findings were
reproduced with a high-calcium (1.05 mM), serum-free
medium (medium 3: a 1:1 ratio of F10:DMEM),
although, overall, the IL-6 levels were lower with the
latter medium (Fig. 1C,D). Fibroma-derived fibroblasts
used as a control expressed on average 5 U/ml IL-6,
being similar to the values of the PP fibroblasts. It is
important to realize that very low numbers of PP fibro-
blasts are thus able to produce several units of IL-6.
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Figure 1. PP fibroblasts secrete low but increased amounts of IL-6 compared to NN fibroblasts under
serum-free culture conditions.
The IL-6 production (A and C) and cell number (B and D) of PP and NN fibroblasts (both n 5 6) were
monitored on 5 consecutive days starting from day 3 after seeding using the B9 assay and cell counts,
respectively. Cells were seeded at 500/cm2 in 12-well plates using medium 1 (A,B) and 3 (C,D). See
Materials and Methods for a description of the media. Closed bars and circles represent PP fibroblasts
and open bars and circles NN fibroblasts. Results are given in mean 6 SEM.
Differences between PP and NN fibroblasts were more
pronounced in the supernatants of larger numbers of
fibroblasts (Table 3).
The IL-6 production by PP fibroblasts is rapid, high
and persisting under serum-stimulated conditions
Using medium 1 supplemented with growth factors,
such as insulin, epidermal growth factor and a pituitary
extract (medium 2), PP and NN fibroblasts were res-
cued from death, but did not show a proliferative
response (Fig. 2B). The IL-6 levels, although higher for
PP fibroblasts, increased more substantially for NN
fibroblasts (Fig. 2A versus Fig. 1A). Differences in IL-
6 production between both types of fibroblasts were
more marked when serum was used as a stimulus.
Medium 4, which is medium 3 containing 5% fetal calf
serum (FCS), was the only culture medium supporting
the proliferation of fibroblasts (Fig. 2D). The number
of both PP and NN fibroblasts doubled during the test-
period of 5 days. The amounts of bioactive IL-6 present
in the supernatants increased about six times using NN
fibroblasts but only two times using PP fibroblasts dur-
ing this period (Fig. 2C). The IL-6 production corrected
for the corresponding cell numbers reached a plateau
level at the beginning of the test (about 10 U/1000 cells)
and persisted in PP fibroblasts throughout the test-
period, whereas comparable levels of IL-6 were pro-
duced only after 1 week of culture in NN fibroblasts
(Table 1). The IL-6 production by PP fibroblasts was
already maximal at 24 h after seeding. The de novo pro-
duction of IL-6 protein by confluent fibroblasts, how-
ever, checked by changing the medium after 6 days of
culture, was not increased in PP fibroblasts when com-
pared to NN fibroblasts (Table 2).
Serum represses the expression of IL-6 mRNA in 
PP fibroblasts
PP and NN fibroblasts cultured with medium 1 had
a clear expression of steady state IL-6 mRNA levels, as
shown in Figure 3. FCS added to medium 1 decreased
the IL-6 message to undetectable levels in all the PP
fibroblast cultures, but only in half of the NN fibroblast
cultures investigated. When using medium 3, or
medium 3 supplemented with FCS the expression of 
IL-6 mRNA was not detectable (not shown). To study
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Figure 2. PP fibroblasts rapidly secrete high and persisting amounts of IL-6 under serum-stimulated con-
ditions.
See legend to Figure 1 for details. Medium 2 is medium 1 supplemented with growth factors. Medium 4 is
medium 3 supplemented with FCS, as described in Materials and Methods .
TABLE 1. IL-6 production by PP and NN fibroblasts using
a serum-containing medium
Psoriasis Normal control
U/1000 cells U/1000 cells P value
Days in culture
3 10.2 6 1.8a 3.1 6 0.7 0.007
4 10.7 6 4.0 2.1 6 0.5 0.004
5 11.7 6 4.9 2.3 6 0.4 0.010
6 10.4 6 1.5 3.1 6 0.7 0.007
7 8.9 6 1.0 7.3 6 3.3 0.080
a The IL-6 activity present in the supernatants of PP and NN fibroblasts (both
n 5 6) was monitored on 5 consecutive days starting from day 3 after seeding
using the B9 assay. IL-6 activities were corrected for the corresponding cell
number and expressed in U/1000 cells fibroblasts. Cells were seeded at 500/cm2
in 12-well plates using medium 4. Results are given in mean 6 SEM. P values
, 0.05 were considered statistically significant.
the mechanism of the inhibitory process we analysed
the effect of cycloheximide. Results showed that the
inhibitory effect of serum components required de 
novo protein synthesis.
Serum and calcium modulate the IL-6 mRNA
expression differently in PP and NN fibroblasts
PP and NN fibroblasts responded differently to
test-sera such as FCS, inactivated FCS, human serum
and a serum-free component, as shown in Figure 4. In
PP fibroblasts all types of serum repressed the IL-6
mRNA expression completely. Unexpectedly, the IL-6
message was also repressed when using the serum-free
component as a supplement. However, in NN fibro-
blasts the repression of IL-6 mRNA expression was
only complete in part of the cultures tested with FCS
and inactivated FCS, but always complete with human
serum. Moreover, the serum-free component even
enhanced the IL-6 message in NN fibroblasts. Cal-
cium, used as supplement, repressed the expression 
of IL-6 mRNA in PP fibroblasts, whereas the IL-6 
message was not affected in NN fibroblasts.
Expression of IL-8 protein and mRNA levels are
similar to IL-6
Apart from IL-6, fibroblasts also secrete IL-8, but
only negligible amounts of IL-1 and TNF-a using con-
ditions with or without serum. The production of IL-6
and IL-8 using different culture conditions are pre-
sented in Table 3, and correspond to the same cultures
of which RNA data is presented in Figure 3. PP fibro-
blasts produced clearly increased amounts of IL-6 and
IL-8 when cultured with both the low and high-calcium
serum-free media. The serum-induced IL-6 production
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Figure 3. Serum represses the expression of IL-6 mRNA in PP
fibroblasts.
The expression of steady-state IL-6 mRNA levels in PP and NN
fibroblasts (both n 5 6) were analysed by Northern hybridization
after 2 days of culture in medium 1, or medium 1 supplemented with
5% FCS. Autoradiography, to detect the message for IL-6 (1.3 kb
band) and GAPDH (1.2 kb band), was carried out at 270°C for 3 and
1 days, respectively. Cycloheximide (CHX: 10 m g/ml) was added 3 h
before harvesting. See text for details. PBMC and THP-1 cells were
used as controls.
TABLE 2. The difference in IL-6 production between PP
and NN fibroblsts is lost during culture
Psoriasis Normal control
U/ml U/ml
Type of supernatant
Day 1 30a 7
Accumulated IL-6 at day 7 38 36
Newly synthesized IL-6 at day 7 45 57
a The IL-6 production of PP and NN fibroblasts (n 5 3) seeded at 500 cells/cm2
and cultured in medium 4 using 12-well plates was measured with the B9 assay
and expressed in U/ml. Supernatants were collected at day 1 and 7 after seed-
ing. Medium was changed 24 h before collecting supernatants at day 7 to analyse
the amount of newly synthesized IL-6. Results of representative cultures are
given.
Figure 4. Serum-dependent repression of IL-6 mRNA expression in PP fibroblasts is not restricted to FCS.
Steady-state IL-6 mRNA levels in PP and NN fibroblasts (n 5 3) were analysed by Northern hybridization after 2 days
of culture in medium 1 supplemented with calcium or different types of serum. The final calcium (Ca21) concentration
was 1.05 mM. FCS, inactivated FCS (FCS2), human serum (HS) and serum-free component (SF-1) were all added to
a final concentration of 5% (v/v). See legend to Figure 3 for details. Results of representative cultures are given. PBMC
were used as a control.
was also elevated in PP fibroblasts after 2 days of cul-
ture (Table 3). This is in line with Figures 1, 2 and Table
1. Differences in the IL-8 production, however, were
completely restored by serum. In fact, the kinetics of
the serum-induced IL-8 production by PP and NN fibro-
blasts were similar (not shown). Fibroblasts did not
express IL-1a , IL-1b or TNF-a mRNA. The expression
of IL-8 mRNA, however, was similar to that of IL-6
mRNA using the different culture conditions. The use
of stimuli like phorbol myristate acetate (PMA),
lipopolysaccharide (LPS), recombinant human IL-1b
and TNF- a enhanced the expression of IL-6 and IL-8
mRNA, but that of IL-1a , IL-1b and TNF-a mRNA
only to a negligible extent (Fig. 5). The expression of
IL-6 and IL-8 mRNA was most profoundly enhanced
by IL-1b . The corresponding amounts of cytokines pre-
sent in the conditioned media of the same fibroblast cul-
ture are given in Table 4. It is important to note that
although fibroblast IL-8 synthesis is similar to that of
IL-6, the differences between PP and NN fibroblasts
were most marked for IL-6. In summary, an inventory
of our findings on the altered IL-6 synthesis in PP fibro-
blasts is given in Table 5.
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TABLE 3. IL-6 and IL-8 production by fibroblasts under
different culture conditionsa
Psoriasis Normal control
IL-6b IL-8c IL-6 IL-8
U/ml pg/ml U/ml pg/ml
Medium Serum
1 2 2961 1600 289 30
1 1 1932 940 74 690
3 2 222 310 21 13
3 1b 2171 1140 194 1650
a The amount of IL-6 and IL-8 present in 48 h supernatants of PP and NN fibrob-
lasts (n 5 3) were measured with the B9 assay and IL-8 ELISA, respectively.
Media used were medium 1 and 3, and these media supplemented with 5%
FCS. Cells were grown on 625 cm2 culture plates to semi-confluence before test-
media were added. Results are given of a representative PP and NN fibroblast
culture.
b Medium 3 supplemented with serum is medium 4.
Figure 5. Fibroblasts express IL-6 and IL-8 mRNA, but not IL-1a ,
IL-1b and TNF-a mRNA.
Steady-state levels of IL-1a , IL-1b , IL-6, IL-8 and TNF-a mRNA in
NN fibroblasts were analysed by Northern hybridization after two
days of culture in different media with and without stimuli.
Autoradiography, to detect the message for IL-1a (2.1 kb band), IL-
1b (1.6 kb band), IL-6 (1.3 kb band), IL-8 (1.8 kb band), TNF-a (1.7
kb band) and GAPDH (1.2 kb band), was carried out for 10, 2, 3, 4,
4 and 1 days, respectively. Results of a representative culture are
given. Experiment was performed in duplo. PBMC and THP-1 cells
were used as controls.
TABLE 4. Cytokine production profile of fibroblasts
Cytokinesa
IL-1 IL-6 IL-8 TNF-a
U/ml U/ml pg/ml U/ml
Medium Stimulus
1 2 0 210 20 0
1 serum 0 169 45 0
3 2 0 15 2 0
3 serumb 0 258 40 0
4 PMA 0 294 53 0
4 LPS 0 13 796 7900 0
4 IL-1b 0 38 603 1050 0
4 TNF-a 0 4523 600 0
a The IL-1, IL-6 and TNF-a activities and IL-8 immunoreactivity present in 48
h supernatants of NN fibroblasts were measured with the D10, B9, WEHI bioas-
say and IL-8 ELISA, respectively. IL-1, IL-6 and TNF-a are expressed in U/ml,
and IL-8 in pg/ml. Media used were medium 1 and 3, these two media supple-
mented with 5% FCS, and medium 4 with stimuli. PMA (50 ng/ml), LPS (10
m g/ml), IL-1b (100 U/ml) or TNF-a (100 U/ml) were added as stimuli to the
cells 14 h before collecting supernatants. Results are given of a representative
culture. The experiment was performed in duplo. Supernatant of LPS-stimu-
lated PBMC contained 56 000 U/ml IL-1; 28 000 U/ml IL-6; 800 pg/ml IL-8 and
15 U/ml TNF-a .
b Medium 3 supplemented with serum is medium 4.
TABLE 5. IL-6 synthesis is altered in PP fibroblastsa
Normal
Psoriasis control
Stimulus
IL-6 protein none 1a 2
FCS 11 1
IL-6 mRNA none 11 11
FCS 2 6
inactivated FCS 2 6
human serum 2 2
serum-free
component 6 11
calcium 6 11
CHX 11 11
a Summary of the B9 assay and Northern hybridization results, with the expres-
sions of IL-6 protein and mRNA given in symbols, 2: absent or low in all exper-
iments; 6: present in part of the experiments; 1/11: present/clearly present
in all experiments. CHX: cycloheximide.
1.7 kb
DISCUSSION
The serum-free production of IL-6 and IL-8 by PP
fibroblasts was increased when compared to NN fibro-
blasts (Fig. 1 and Table 3). The growth factors present
in medium 2 enhanced the production of IL-6 (Fig. 2)
and IL-8 (not shown) most markedly in NN fibroblasts,
resulting in a reduced difference in cytokine production
between the two types of fibroblasts. Kinetics showed
that PP fibroblasts rapidly produced high and persist-
ing amounts of IL-6 under serum-stimulating con-
ditions. The production of IL-6, not of IL-8, was
significantly enhanced in PP fibroblasts when compared
to NN fibroblasts (Table 1). Using confluent PP fibro-
blasts (6 days after seeding), however, we observed that
the serum-induced IL-6 (Table 2) was similar or even
less than their normal counterparts. This may explain
why the differences in IL-6 production were lost after
a culture-period of 1 week. It remains possible that PP
fibroblasts display an altered post-translational
modification of IL-6 resulting, for example, in a
decreased aggregation of IL-6 monomeres which
express more activity in the B9 assay,22 or in a prolonged
half-life of the protein. However, our finding that dif-
ferences in IL-6 levels are already present in super-
natants collected rapidly (24 h) after seeding do not
favour an altered half-life of PP fibroblast-derived IL-
6 protein.
The IL-6 production of normal human dermal
fibroblasts is highly serum-dependent, as already
reported for normal human monocytes and ker-
atinocytes.23,24 Normal human cells typically do not
express IL-6 in the absence of a stimulatory signal.25
Fibroblasts derived from lesional psoriatic skin, how-
ever, are less dependent on external stimuli for their 
IL-6 production. The enhanced production of IL-6 is
not unique for PP fibroblasts. Constitutive production
of IL-6, without exogenous stimuli, has already been
described for dermal fibroblasts derived from affected
skin sites from patients with systemic sclerosis,26
synovial fibroblasts from patients with rheumatic
arthritis,27 mesothelioma cell lines,28 and peripheral
blood monocytes from psoriasis patients.18 This suggests
that overproduction of IL-6 could represent a general
feature of affected mesenchymal cells thereby con-
tributing to the maintenance of inflammation.
IL-6 production is regulated at the level of tran-
scription and mRNA stability.29,30 Transcription of the
human IL-6 gene is normally enhanced by serum as evi-
denced by the location of the c-fos serum-responsive
element homology (c-fos SRE) within the IL6 pro-
moter.31 PP and NN fibroblasts had a clear but similar
expression of steady-state IL-6 mRNA levels using
medium 1 (0.15 mM calcium). This protein-deficient
medium may be unable to support the production of a
repressor protein of IL-6 mRNA transcription.
Unexpectedly, this protein is present in serum-contain-
ing media, as explained later on. One also cannot
exclude the possibility that medium 1 has a stabilizing
effect on IL-6 mRNA. The corresponding IL-6 protein
levels, especially of PP fibroblasts (Table 3), do not
favour, however, inhibition of IL-6 translation. With
medium 3 (1.05 mM calcium) the message for IL-6 is
not detectable. Normal human keratinocytes, grown in
a serum-free medium containing 0. 15 mM calcium, did
not express detectable IL-6 mRNA levels using
Northern hybridization. Low levels of IL-6 mRNA
could be induced in these cells by treatment with 1.8
mM calcium.21 This suggests cell-type specific differ-
ences in the induction of IL-6 gene expression. Serum
reduced the IL-6 message completely in all the PP
fibroblast cultures investigated. The expression of IL-6
mRNA is, however, reported to be induced in human
foreskin, synovial and bone marrow stromal fibroblasts
within several hours in response to serum when fibro-
blasts were made quiescent by serum deprivation and
RNA levels were analysed using blot hybridization with
poly(A1) RNA or PCR amplified products.32-34 Apart
from technical differences, our findings using human
dermal fibroblasts may be attributed to tissue-specific
serum-responsiveness of fibroblasts. The repressing
effect of serum on the IL-6 mRNA expression in PP
fibroblasts could be completely abolished by cyclohex-
imide treatment. This suggests that at least with medium
1, serum induces a labile protein which represses the
levels of IL-6 mRNA.
Experiments were performed to determine
whether the inhibiting effect was specific for FCS. In PP
fibroblasts the IL-6 mRNA expression was repressed
by all test-sera. Complement factors, known to enhance
the IL-6 production of stimulated human monocytes,35
did not affect the IL-6 mRNA expression in our exper-
iments, as shown by the use of inactivated serum.
Furthermore, the use of human serum showed that a
species-specific serum component did not seem to be
involved. However, the repression of the IL-6 message
in NN fibroblasts was more susceptible to human serum
than FCS. Whether the presence of cytokines, their sol-
uble receptors or anti-cytokine autoantibodies in serum
contributes to differences in responsiveness between
PP and NN fibroblasts remains to be resolved.36,37 The
use of a serum-free supplement or calcium repressed
the expression of IL-6 mRNA in PP fibroblasts, whereas
the levels of IL-6 mRNA were unaffected or even
enhanced in NN fibroblasts. Components of serum-free
supplement (e.g. albumin, ethanolamines, insulin,
transferrin and free fatty acids) and calcium are
reported to be inducers of IL-6 production.21,38,39 Thus,
on the one hand our findings confirm that serum fac-
tors and calcium induce production of IL-6 in normal
human dermal fibroblasts and on the other hand indi-
cate that the IL-6 production in PP fibroblasts is regu-
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lated differently by serum factors and calcium. Factors
present in FCS and human serum as well as several
growth factors were reported to induce proliferation in
PP fibroblasts to a higher extent when compared to NN
fibroblasts.40,41 However, we and others did not observe
differences in cell growth between both types of fibro-
blasts.5 Our study suggests that IL-6, being anti-mitotic
for fibroblasts, is not primarily involved in the regula-
tion of PP fibroblast growth in vitro, as is the case for
PDGF.16 The altered IL-6 synthesis of multi-passaged
PP fibroblasts confirms early studies which demon-
strated several inherent abnormalities such as increased
production of extracellular matrix components, intra-
cellular signalling and resistence to therapeutics result-
ing in an hyperactive state of these cells in vitro.42–44
Human fibroblasts are, apart from IL-6, potent 
producers of IL-8, but do not produce IL-1a , IL-1 b or
TNF-a even when using potent stimuli like PMA, LPS
and the cytokines IL-1b and TNF-a . These cells express
negligible amounts of the corresponding mRNA (Table
4 and Fig. 5). Fibroblasts derived from different tissues
display some discrepancies with regard to the expres-
sion of IL-1.45 Espinoza and colleagues showed that
anti-IL-1b polyclonal antibody partly neutralized the
fibroblast mitogenic activity of supernatants of PP
fibroblasts. Their results indicate that the latter assay
probably is more sensitive when compared to the D10
assay.16 The production of IL-8 was similar to that of 
IL-6. However, differences in the serum-induced pro-
duction of IL-6 protein between PP and NN fibroblasts
were specific for this cytokine (Table 3). Taken together,
our findings show that PP fibroblasts display an altered
synthesis of IL-6 in vitro, which is regulated differently
by serum factors and calcium. These alterations are
summarized in Table 5. The in vivo relevance of IL-6 to
skin physiology and pathology has previously been
extensively reviewed.46,47 During cutaneous inflamma-
tion IL-6 maintains the inflammatory response by
attracting leucocytes and activating inflammatory and
resident cells via the induction of cytokines and adhe-
sion molecules. Moreover, fibroblast-derived IL-6 may
even enhance antigen presentation as IL-6 can induce
the expression of the HLA-B7 gene in human fibro-
blasts.48 Cutaneous IL-6 production is drastically
increased during injury, infections, neoplasia and
autoimmune diseases. We provide evidence that der-
mal fibroblasts are an important source of the elevated
IL-6 levels in psoriatic lesions. The contribution of IL-
6 to the pathogenesis of psoriasis is still obscure.
However, the findings that vitamin D3 analogs are an
efficient anti-psoriatic therapy and that these sub-
stances decrease fibroblast-derived IL-6 and IL-8 
levels in vitro imply a role of dermal IL-6 and IL-8 
in psoriasis.49,50 In our opinion dermal fibroblasts are
actively involved in maintaining the inflammatory
response in psoriatic lesions.
MATERIALS AND METHODS
Patients and controls
Skin samples were obtained from ten otherwise healthy
patients (Outpatient Department of Dermatology, University
Hospital Rotterdam-Dijkzigt) with active plaque-type pso-
riasis after informed consent. Patients remained untreated for
at least 3 weeks before entering the study. Ten individuals
without history or signs of skin disease, undergoing abdomi-
nal or breast plastic surgery (Sint Franciscus Hospital,
Rotterdam) served as normal healthy controls. All skin 
samples were collected after approval of the institutional
medical ethical committee (MEC 104.050/SPO/1990/30).
Culturing of fibroblasts
Split-skin specimens from PP and NN skin, including epi-
dermis and superficial dermis, were obtained using a portable
dermatome (Davol Inc., Cranston, Rl). Epidermis was sep-
arated from dermis via trypsinization. Primary cultures of
fibroblasts were obtained by plating dermal parts in a 25 cm2
culture flask (Becton Dickinson, Plymouth, UK). The dermal
pieces were allowed to attach after which 2 ml of culture
medium was added to the flask. The culture medium consisted
of Dulbecco's modification of Eagle's medium (DMEM:
Gibco Ltd., Paisley, Scotland) supplemented with 10% FCS
(Gibco), 100 U/ml penicillin and 100 ug/ml streptomycin. At
confluence, cells were subcultured via trypsinization. After
the first passage fibroblast cultures were free of epidermal
cells. Contamination with mycoplasma species was excluded
by testing antibiotic-free culture supernatants for adenosine
phosphorylase activity (Mycotest: Gibco). For experiments,
fibroblasts of passageno. 2 to 6 were collected, trypsinization
was stopped with 100 m g/ml trypsin inhibitor and cells were
extensively rinsed with PBS. Viability was determined by 
trypan blue exclusion.
Fibroblast-conditioned medium
Fibroblasts were plated in 12-well plates (Costar,
Cambridge, MA) at a density of 500 viable cells/cm2, using 1
ml of one of the following media: (1) a low-calcium (0.15 mM),
serum-free medium (medium 1: keratinocyte basal medium,
KBM/unsupplemented MCDB 153: Clonetics, San Diego,
CA); (2) medium 1 supplemented with 5 m g/ml insulin, 10
ng/ml human recombinant epidermal growth factor, 0.5 m g/ml
hydrocortisone, 0.4% (v/v) bovine pituitary extract and 50
U/ml gentamicine sulphate (medium 2: keratinocyte growth
medium, KGM/supplemented MCDB 153: Clonetics); (3) a
high-calcium (1.05 mM), serum-free medium consisting of
Ham’s F10 (Gibco) and DMEM in a ratio of 1:1 supplemented
with antibiotics (medium 3); and (4) medium 3 supplemented
with 5% FCS (medium 4). The effects of different types of
serum on the production of cytokines were investigated using
another culture system, described below. For kinetic studies,
cells and supernatants were collected on 5 consecutive days
starting from day 3 after seeding. Each test-condition was
tested in triplicates. Supernatants were collected by centrifu-
gation, supplemented with 0.1% bovine serum albumin in
case of serum-free supernatants and stored at 280°C. Cells
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present in the same wells were collected via trypsinization and
counted microscopically (Carl Zeiss, Germany).
Bioassays for IL-1, IL-6 and TNF-a
IL-1 bioactivity was measured using a subline of a cloned
murine T cell line D10.G4.1, designated D10(N4)M (kindly
provided by Dr S. Hopkins, Manchester, UK).51 IL-6 bioac-
tivity was measured using a murine hybridoma cell line B9
(kindly donated by Prof. Dr L. Aarden, Amsterdam, The
Netherlands).23 Proliferation of the cytokine dependent cell
lines D10 and B9 was measured via [3H]deoxythymidine
incorporation. TNF-a bioactivity was measured using the
murine fibroblast cell line WEHI 164.13 (kindly provided by
Dr W. Buurman, Maastricht, the Netherlands).52 The MTT
cytotoxicity assay was used to measure the viability of WEHI
cells.53 Recombinant human IL-1b (UBI, Lake Placid, NY),
IL-6 (Prof. Dr L. Aarden) and TNF-a (UBI) served as posi-
tive controls for the D10, B9 and WEHI assay, respectively.
Cytokine activities of the samples were corrected for back-
ground activity of the culture medium and expressed in U/ml
or in U/1000 cells, with 1 U/ml corresponding with half-max-
imal response.
IL-8 ELISA
IL-8 immunoreactivity was measured by ELISA, as
described previously.54 Dr K. Matsushima (Tochigi-ken,
Japan) kindly provided the monoclonal anti-IL-8 IgG1 (WS4)
and the rabbit polyclonal anti-IL-8 antibody.55 Recombinant
human IL-8 (Dainippon, Japan) served as a positive control.
Northern hybridization
For RNA analysis fibroblasts were grown on 625 cm2 cul-
ture plates (Gibco) until 60% confluence was reached.
Subsequently, cells were rinsed 2 times with PBS and cultured
for 48 h under test-conditions. The test-conditions comprised
media 1 to 4 and medium 1 supplemented with calcium and
different types of serum. The different sera comprised FCS,
FCS treated 30 min at 56°C (inactivated FCS or FCS2), pooled
human AB serum (HS: Red Cross Blood Center, Rotterdam,
The Netherlands) and serum-free component (SF-1: Costar)
and were tested at 5% (v/v). Calcium (hydrated calcium-
chloride) was added to a final concentration of 1.05 mM.
Cycloheximide (Sigma) was added to some plates (10 m g/ml)
3 h before cell harvesting. Supernatants were collected and
cells were harvested using a rubber policeman (Costar). Total
cellular RNA was isolated using the guanidium thiocyanate
extraction procedure.56 RNA samples of 25 m g were size frac-
tionated by electrophoresis through 1% agarose and 17%
formaldehyde gels, transferred to Nytran N nylon membranes
(Schleicher and Schuell, Dassel, Germany),57 and hybridized
according to Jeffreys et al. with 32P-labelled cDNA probes.58,59
Autoradiography was carried out with Kodak films at 270°C
for 1 to 10 days. Hybridized probes were removed from the
nylon membranes according to Sambrook et al.57
Probes
Probes were derived from cDNA: IL-1a , a 0.6 kb EcoRI-
HindIII fragment (Biogen, Basel, Switzerland); IL-1b , a 1.3
kb PstI fragment (Genetics Institute, Cambridge, MA); IL-6,
a 0.3 kb EcoRI-HindIII fragment;60 IL-8, a 1.3 kb EcoRI frag-
ment;61 TNF-a , a 0.6 kb EcoRI-ClaI fragment (Celltech,
Berkshire, UK); and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH), a 0.7 kb EcoRI-PstI fragment,62 serving as
a control for RNA loading.
Controls
Several cellular controls were used for the expression of
cytokines at the protein and mRNA level: a fibroma-derived
fibroblast cell line; NN fibroblasts stimulated with 50 ng/ml
PMA (Sigma Chemie, Bornem, Belgium), 10 m g/ml LPS
(Escherichia coli 026:B6, Difco Laboratories, Detroit, MI),
100 U/ml recombinant human IL-1b or 100 U/ml recombi-
nant human TNF-a ; and PBMC and the myelomonocytic cell
line THP-1 stimulated with LPS. Stimuli were added 14 h
before cell harvesting.
Statistical analysis
Bioassay and ELISA results were analysed with the
Wilcoxon Rank Sum Test using STATATM (Computing
Resource Center, Los Angeles, CA). P values 0.05 were con-
sidered statistically significant.
Acknowledgements
We thank Mrs K. Stadel Pedersen for her expert
technical assistance with the IL-8 ELISA, Dr J.
Ramselaar for providing skin samples of normal con-
trols, Miss P. Assems for typing the manuscript and Mr
T. van Os for preparing the figures.
REFERENCES
1. Bos JD (1988) The pathomechanisms of psoriasis; the 
skin immune system and cyclosporine (review). Br J Dermatol
118:141–155.
2. Christophers E, Schubert C (1986) Psoriasis. In Thody AJ,
Friedmann PS (eds) Scientific basis of dermatology (a physiological
approach), Churchill Livingstone Publisher, London, pp 151–174.
3. Krueger GG, Manning DD, Malouf J, Ogden B (1975) Long-
term maintenance of psoriatic human skin on congenitally athymic
(nude) mice. J Invest Dermatol 64:307–312.
4. Fraki JE, Briggaman RA, Lazarus GS (1983) Trans-
plantation of psoriatic skin onto nude mouse. J Invest Dermatol
80:31S–35S.
5. Baden HP, Kubilus J, Macdonald MJ (1981) Normal and
psoriatic keratinocytes and fibroblasts compared in culture. J Invest
Dermatol 76:53–55.
6. Karasek MA (1972) Dermal factors affecting epidermal
cells in vitro. J Invest Dermatol 59:99–101.
7. Saiag P, Coulomb B, Lebreton C, Bell E, Dubertret L (1985)
Psoriatic fibroblasts induce hyperproliferation of normal ker-
atinocytes in a skin equivalent model in vitro. Science 230:669–672.
8. Priestley GC, Lord R (1990) Fibroblast-keratinocyte inter-
actions in psoriasis: failure of psoriatic fibroblasts to stimulate 
keratinocyte proliferation in vitro. Br J Dermatol 123:467–472.
9. Saiag P, Coulomb B, Rowland-Payne CM, Dubertret L,
Touraine R (1986) Lasers, dermal fibroblasts and psoriasis. Br J
Dermatol 115:744–745.
IL-6 production by psoriatic fibroblasts / 77
10. Mauviel A, Temime M, Charron D, Loyau G, Pujol J-P
(1991) Induction of interleukin-1b production in human dermal
fibroblasts by interleukin-1 a and tumor necrosis factor- a .
Involvement of protein kinase-dependent and adenylate cyclase-
dependent regulatory pathways. J Cell Biochem 47:174–183.
11. Van Damme J, Cayphas S, Opdenakker G, Billiau A, Van
Snick J (1987) Interleukin 1 and poly(rI) poly(rC) induce production
of a hybridoma growth factor by human fibroblasts. Eur J Immunol
17:1–7.
12. Larsen CG, Anderson AO, Oppenheim JJ, Matsushima K
(1989) Production of interleukin-8 by human dermal fibroblasts and
keratinocytes in response to interleukin-1 or tumour necrosis factor.
Immunology 68:31–36.
13. Ristow HJ (1987) A major factor contributing to epidermal
proliferation in inflammatory skin diseases appears to be interleukin
1 or a related protein. Proc Natl Acad Sci USA 84:1940–1944.
14. Grossman RM, Krueger J, Yourish D, Granelli-Piperno A,
Murphy DP, May LT, Kupper TS, Sehgal PB, Gottlieb AB (1989)
Interleukin 6 is expressed in high levels in psoriatic skin and stimu-
lates proliferation of cultured human keratinocytes. Proc Natl Acad
Sci USA 86:6367–6371.
15. Tuschil A, Lam C, Halsberger A, Lindley I (1992)
Interleukin-8 stimulates calcium transients and promotes epidermal
cell proliferation. J Invest Dermatol 99:294–298.
16. Espinoza LR, Espinoza CG, Cuéllar ML, Scopelitis E,
Silveira LH, Grotendorst GR (1994) Fibroblast function in psoriatic
arthritis. II. Increased expression of b platelet derived growth factor
receptors and increased production of growth factor and cytokines.
J Rheumatol 21:1507–1514.
17. Prens EP, Benne K, Van Damme J, Bakkus M, Brakel K,
Benner R, Van Joost T (1990) Interleukin 1 and interleukin 6 in pso-
riasis. J Invest Dermatol 95:121S–124S.
18. Neuner P, Urbanski A, Trautinger F, Möller A, Kirnbauer
R, Kapp A, Schopf E, Schwarz T, Luger TA (1991) Increased IL-6
production by monocytes and keratinocytes in patients with psoria-
sis. J Invest Dermatol 97:27–33.
19. Gearing AJH, Fincham NJ, Bird CR, Wadhwa M, Meager
A, Cartwright JE, Camp RDR (1990) Cytokines in skin lesions of
psoriasis. Cytokine 2:68–75.
20. Gillitzer R, Berger R, Mielke V, Muller C, Wolff K, Stingl
G (1991) Upper keratinocytes of psoriatic lesions express high levels
of NAP-1 /IL-8 mRNA in situ. J Invest Dermatol 97:73–79.
21. Elder JT, Sartor CI, Boman DK, Benrazavi S, Fisher GJ,
Pittelkow MR (1992) Interleukin-6 in psoriasis: expression and mito-
genicity studies. Arch Dermatol Res 284:324–332.
22. May LT, Santhanam U, Sehgal PB (1991 ) On the multimeric
nature of natural human intereukin-6. J Biol Chem 266:9950–9955.
23. Aarden LA, De Groot ER, Schaap OL, Lansdorp PM
(1987) Production of hybridoma growth factor by human monocytes.
Eur J Immunol 17:1411–1416.
24. Kirnbauer R, Köck A, Schwarz T, Urbanski A, Krutmann
J, Borth W, Damm D, Shipley G, Ansel JC, Luger TA (1989) IFN-b 2,
B cell differentiation factor 2, or hybridoma growth factor (IL-6) is
expressed and released by human epidermal cells and epidermoid
carcinoma cell lines. J Immunol 142:1922–1928.
25. Kishimoto T (1989) The biology of interleukin-6. Blood
74:1–10.
26. Feghali CA, Bost KL, Boulware DW, Levy LS (1992)
Mechanisms of pathogenesis in scleroderma I. Overproduction of
interleukin 6 by fibroblasts cultured from affected skin sites of
patients with scleroderma. J Rheumatol 19:1207–1211.
27. Bucala R, Ritchlin C, Winchester R, Cerami A (1991)
Constitutive production of inflammatory and mitogenic cytokines by
rheumatoid synovial fibroblasts. J Exp Med 173:569–574.
28. Schmitter D, Lauber B, Ragg B, Stahel RA (1992)
Hematopoietic growth factors secreted by seven human pleural
mesothelioma cell lines: interleukin-6 production as a common 
feature. Int J Cancer 51:296–301.
29. Zhang Y, Lin J-X, VilŁek J ( 1990) Interleukin-6 induction
by tumor necrosis factor and interleukin-1 in human fibroblasts
involves activation of a nuclear factor binding to a kB-like sequence.
Mol Cell Biol 10:3818–3823.
30. Elias JA, Lentz V (1990) IL-1 and tumor necrosis factor syn-
ergistically stimulate fibroblast IL-6 production and stabilize IL-6
messenger RNA. J Immunol 145:161–166.
31. Ray A, Sassone-Corsi P, Seghal PB (1989) A multiple
cytokine- and second messenger-responsive element in the enhancer
of the human interleukin-6 gene: similarities with c-fos gene regu-
lation. Mol Cell Biol 9:5537–5547.
32. Goodman L, Stein GH (1994) Basal and induced amounts
of interleukin-6 mRNA decline progressively with age in human
fibroblasts. J Biol Chem 269:19250–19255.
33. Guba SC, Sartor Cl, Gottschalk LR, Ye-Hu J, Mulligan T,
Emerson SG (1992) Bone marrow stromal fibroblasts secrete inter-
leukin 6 and granulocyte-macrophage colony-stimulating factor in
the absence of inflammatory stimulation: demonstration by serum-
free bioassay, enzyme-linked immunosorbent assay, and reverse tran-
scriptase polymerase chain reaction. Blood 80:1190–1198.
34. Rosenbaum JT, Cugnini R, Tara DC, Hefeneider S, Ansel
JC ( 1992) Production and modulation of interleukin 6 synthesis by
synoviocytes derived from patients with arthritic disease. Annal
Rheum Dis 51:198–202.
35. Montz H, Koch KC, Zierz R, Gotze O (1991) The role of
C5a in interleukin-6 production induced by lipopolysaccharide or
interleukin-1. Immunology 74:373–379.
36. Maliszewski CR, Sato TA, Davison B, Jacobs CA,
Finkelman FD, Fanslow WC (1994) In vivo biological effects of
recombinant soluble interleukin-4 receptor. Proc Soc Exp Biol Med
206:233–237.
37. Hansen MB, Svenson M, Diamant M, Bendtzen K 
(1993) High-affinity IgG autoantibodies to IL-6 in sera of normal
individuals are competitive inhibitors of IL-6 in vitro. Cytokine
5:72–80.
38. Shacter E, Arzadon GK, Williams JA (1993) Stimulation of
interleukin-6 and prostaglandin E2 secretion from peritoneal
macrophages by polymers of albumin. Blood 82:2853–2864.
39. Schillaci R, Eugui EM, Roldan A (1994) Insulin effect on
interleukin 1 (IL-1) and interleukin 6 (IL-6) production by
lipopolysaccharide-stimulated human monocytes. Horm Metab Res
26:113–115.
40. Espinoza LR, Aguilar JL, Espinoza CG, Cuéllar ML,
Scopelitis E, Silveira LH (1994) Fibroblast function in psoriatic 
arthritis. I. Alteration of cell kinetics and growth factor responses. 
J Rheumatol 21:1502–1506.
41. Priestley GC, Adams LW (1985) Mitogenic effects of sera
from normal and psoriatic subjects on human skin fibroblasts. Arch
Dermatol Res 277:13–15.
42. Priestley GC, Adams LW (1983) Hyperactivity of fibro-
blasts cultured from psoriatic skin. II. Synthesis of macromolecules.
Br J Dermatol 109:157–162.
43. Raynaud F, Evain-Brion D (1991) Protein kinase C activity
in normal and psoriatic cells: cultures of fibroblasts and lymphocytes.
Br J Dermatol 124:542–546.
44. MacLaughlin JA, Gange W, Taylor D, Smith E, Holick MF
(1985) Cultured psoriatic fibroblasts from involved and uninvolved
sites have a partial but not absolute resistance to the proliferation-
inhibition activity of 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci
USA 82:5409–5412.
45. Yamato K, El-Hajjoui Z, Koeffler HP (1991) Expression of
hematopoietic growth factor RNAs in human mesenchymal cells
from various organs. Leukemia research 15:551–558.
46. Turksen K, Kupper TS, Degenstein L, Williams I, Fuchs E
(1992) Interleukin 6: Insights to its function in skin by overexpression
in transgenic mice. Proc Natl Acad Sci USA 89:5068–5072.
47. Sehgal PB ( 1990) Interleukin-6: molecular pathophysiol-
ogy. J Invest Dermatol 94:2S–6S.
78 / Debets et al. CYTOKINE, Vol. 8, No. 1 (January 1996: 70–79)
IL-6 production by psoriatic fibroblasts / 79
48. May LT, Helfgott DC, Seghal PB ( 1986) Anti-beta-inter-
feron antibodies inhibit the increased expression of HLA-B7 mRNA
in tumor necrosis factor-treated human fibroblasts: structural studies
of the beta 2 interferon involved. Proc Natl Acad Sci USA
83:8957–8961.
49. Srviastava MD, Deluca H, Ambrus JL (1994) Inhibition of
IL-6 and IL-8 production in human fibroblast cell lines by 1,25 (OH)2
vitamin D3 and two of its analogs with lower calcemic activity. Res
Commun Chem Pathol Pharmacol 83:145–150.
50. Larsen CG, Kristensen M, Paludan K, Deleuran B, Thomsen
MK, Zachariae C, Kragballe K, Matsushima K, Thestrup-Pedersen
K (1991) 1,25 (OH)2-D3 is a potent regulator of interleukin-1 induced
interleukin-8 expression and production. Biochem Biophys Res Com
176:1020–1026.
51. Hopkins SJ, Humphreys M (1989) Simple, sensitive and
specific bioassay of interleukin 1. J Immunol Meth 120:271–276.
52. Espevik T, Nissen-Meyer J (1986) A highly sensitive cell
line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necro-
sis factor from human monocytes. J Immunol Meth 95:99–105.
53. Mosmann TJ (1983) Rapid colorimetric assay for cellular
growth and survival: application to proliferation and cytotoxicity
assays. J Immunol Meth 65:55–63.
54. Deleuran B, Iversen L, Kristensen M, Field M, Kragballe
K, Thestrup-Pedersen K, Stengaard-Pedersen K (1994) Interleukin-
8 secretion and 15-lipoxygenase activity in rheumatoid arthritis: in
vitro anti-inflammatory effects by interleukin-4 and interleukin-10,
but not by interleukin-1 receptor antagonist protein. Br J Dermatol
33:520–525.
55. Ko Y, Mukaida N, Panyutich A, Voitenok NN, Matsushima
K, Kawai T, Kasahara T (1992) Establishment of a sensitive enzyme-
linked immunosorbent assay for human interleukin 8. J Immunol
Method 149:227–235.
56. Chomczynski P, Sacchi N (1987) Single-step method of RNA
isolation by acid guanidium thiocyanate-phenol-chloroform extrac-
tion. Anal Biochem 162:156–159.
57. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular
cloning: a laboratory manual. Cold Spring Harbor Laboratory Press,
New York (second edition), pp 7.43–7.50 and 9.58.
58. Jeffreys AJ, Flavell RA ( 1977) A physical map of the DNA
regions flanking the rabbit, b -globin gene. Cell 12:429–439.
59. Feinberg AP, Vogelstein B ( 1983) A technique for radio-
labeling DNA restriction endonuclease fragments to high specific
activity. Anal Biochem 132:6–13.
60. Brakenhoff JPJ, De Groot ER, Evers RF, Pannekoek H,
Aarden LA (1987) Molecular cloning and expression of hybridoma
growth factor in Escherichia coli. J Immunol 139:4116–4121.
61. Dixit VM, Green S, Sarma V, Holzman L, Wolf FW,
O'Rouke K, Ward PA, Prochownik EV, Marks RM (1990) Tumor
necrosis factor-a induction of novel gene products in human endo-
thelial cells including a macrophage-specific chemotaxin. J Biol 
Chem 265:2973–2980.
62. Benham FJ, Hodgkinson S, Davies KE (1984) A glycer-
aldehyde-3-phosphate dehydrogenase pseudogene on the short arm
of the human X chromosomes defines a multigene family. EMBO J
3:2635–2640.
